Rossari Biotech Ltd

Rossari Biotech Expands Capacity & Reports Strong Q4 FY26 Results 📈

• Commissioned additional 15,000 MTPA ethoxylation capacity at Dahej, raising total capacity to 66,000 MTPA

• Q4 FY26 revenue reached ₹684.9 crore, up 18.2% year-on-year

• Full-year FY26 revenue grew 15.2% to ₹2,396.4 crore

• HPPC segment contributed 77% to FY26 revenue

• TSC segment contributed 17% to FY26 revenue

• AHN segment contributed 6% to FY26 revenue

• Q4 FY26 EBITDA margin at 11.3%

• Q4 FY26 PAT margin improved to 6.7%

• Core segments excluding Institutional and B2C delivered EBITDA margin of 14% in FY26

• Set up new R&D facility in Koparkhairane, Navi Mumbai